
Antiretroviral drugs do not interfere with bryostatin-mediated HIV-1 latency reversal
Keywords: AIDS, acquired immunodeficiency syndrome; ATP, Atripla®; BRY, bryostatin-1; cART, combination of antiretroviral therapy; DMSO, dimethyl sulfoxide; EFV, efavirenz; EGFP, enhanced green fluorescent protein; ELISA, enzyme-linked immunosorbent assay; FBS, fet